Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RIG, got out of it, a bit risky for my taste!!
$CRC and $SM might breakout today
$AIM has a gap around 2.05, I hope it fills.
Posted yesterday; I thought it would happen!!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155130700
We thought that the prices of oil stocks will rebound in 4-6 weeks; it seems that they will go BK. Are you still holding these stocks?
Do you see what is going on with oil stocks?
Trump to consider stopping Saudi oil imports, sees price drop as short-term
https://www.investing.com/news/commodities-news/trump-to-consider-stopping-saudi-oil-imports-sees-price-drop-as-shortterm-2145741
We better do a good DD, especially for those with high debt.
https://www.cnn.com/2020/04/20/business/oil-price-crash-bankruptcy/index.html
This time does not seem to be a good time to buy/hold oil stock IMO. It seems that BK is looming for many of them at these rates.
This would boost the market big time. Any chance of bailing out small oil companies?
Why is that AF? small business loan approval?
What if they get a bail out money. These kinds of stocks depend on your risk tolerance. They can go either way.
Do you think $SM, RIG, CRC, and other small companies will survive with the low oil prices for long?
$SM loaded 11k shares and ready!!
I certainly would not touch my oil stocks till they go back to late Feb/early March prices.
I see that there is some anger that oil finally caught some fire. There were so stupid gaps in many other weak stocks. Just enjoy the ride . It also seem that some missed the bottom.
Go to finviz.com and hit future . It is out there.
Actually $6.5
https://finviz.com/futures.ashx
I see @1.25
Because the president is talking about opening up the country, and the possibility of GILD drug to treat CV.
Market future is almost up 1000 points now.
Oil Future is now up more than $6. Fingers crossed-heavy in several oil stocks.
OIL Stocks - no bottom yet!!
OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing Based Antibiotic Susceptibility Testing in Multi-Center Study
Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species and 21 antibiotic drugs
NGS-based testing reached 100% agreement with reference culture-based testing for 32 pathogen-drug pairs and 89% across all 129 pathogen-drug combinations evaluated
The comprehensive study on NGS-based antibiotic susceptibility testing was based on 620 isolates from more than 2,000 patients collected at nine medical centers across the U.S.
VIENNA, Austria and GAITHERSBURG, Md., April 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that a study on the feasibility and potential of antibiotic susceptibility testing and bacterial pathogen identification using next-generation sequencing (NGS) has been pre-published in the Journal of Clinical Microbiology. The study was performed by its newly acquired subsidiaries Ares Genetics GmbH and Curetis GmbH, and scientists at the Max Perutz Labs (Austria), a joint venture of the University of Vienna and the Medical University of Vienna, and the Mayo Clinic (Rochester, MN, U.S.A.).
The article titled, “Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb - An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial” (Ref. 1) reports on a study evaluating the performance of pathogen identification and antibiotic susceptibility testing based on whole genome DNA sequencing (WGS) using Ares Genetics’ AI-powered cloud-based bioinformatics platform ares-genetics.cloud and its underlying reference database, ARESdb.
WGS-predicted susceptibility to antibiotics showed 89% categorical agreement with the current reference method of broth microdilution susceptibility testing across a total of 129 pathogen-drug pairs analyzed. Categorical agreement exceeded 90% in 78, and reached 100% in 32 pathogen-drug pairs. For the taxonomic identification of the isolated bacterial pathogens, WGS showed 99% and 93% concordance with the MALDI-ToF reference method at the genus and species levels, respectively.
The study evaluating the AI-powered ares-genetics.cloud platform and the underlying ARESdb reference database included 12 pathogenic bacterial species and 21 antibiotic compounds covering common lower respiratory tract pathogens and is likely one of the most comprehensive peer-reviewed reports on the performance of WGS in predicting susceptibility to antibiotics in a multi-center U.S. trial.
Dr. Andreas Posch, CEO of Ares Genetics and senior author of the study, commented, “This multi-center study clearly demonstrates the feasibility and potential of next-generation sequencing based antibiotic susceptibility testing using our AI-powered cloud platform. Already today, we are offering cloud-based data interpretation and next-generation sequencing services for research use which we intend to roll out more broadly based on these validating results. Equally important, we learned through the study how to optimize our reference database, ARESdb, and improve our predictive models to further advance to applications in clinical practice.”
In this study, the investigators analyzed WGS data of a total of 620 bacterial strains isolated from more than 2,000 clinical samples collected from patients with suspected lower respiratory tract infections at nine hospitals across the U.S. The samples were originally collected for a U.S.-FDA study for the validation of the now FDA-cleared Unyvero LRT syndromic multiplex PCR panel by Curetis. Species identity of the isolated pathogens and their susceptibility to antibiotics were analyzed using MALDI-ToF and broth microdilution, respectively, as best-in-class reference methods according to current practice.
The WGS data analysis was performed using Ares Genetics’ proprietary database, ARESdb, with state-of-the-art open-source tools and public data. At the time of the study, ARESdb comprised of curated genotype-phenotype data for approximately 35,000 bacterial strains. To date, ARESdb has further grown containing matched whole-genome sequencing and antibiotic susceptibility data for more than 50,000 bacterial strains and more than 100 antibiotics.
Microbial infections and antibiotic resistance have become major healthcare challenges with rapidly spreading antimicrobial resistance estimated to have caused 700,000 deaths globally in 2016, a number that is projected to dramatically increase to 10 million deaths annually by 2050 if no countermeasures are taken (Ref. 2). At the same time, few novel antibiotics are in development and prominent pharmaceutical companies have cut back their R&D efforts in the infectious diseases space. In the absence of novel treatment options, we believe novel diagnostic approaches to allow for rapid identification of causative pathogens and their susceptibility to available treatment options are urgently needed to guide appropriate therapy of patients while enabling prudent and informed use of antibiotics.
The study was supported through funding provided by the Austrian Research Promotion Agency and the Vienna Business Agency.
References
Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb - An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. Ines Ferreira, Stephan Beisken, Lukas Lueftinger, Thomas Weinmaier, Matthias Klein, Johannes Bacher, Robin Patel, Arndt von Haeseler and Andreas E. Posch. 2020. Journal of Clinical Microbiology, DOI: 10.1128/JCM.00273-20
The Review on Antimicrobial Resistance. 2016. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance, chaired by Jim O’Neill, Wellcome Trust & HM Gove
For further information, please register on the Ares Genetics cloud platform:
https://ares-genetics.cloud/
or contact
Ares Genetics GmbH
Karl-Farkas-Gasse 18
A-1030 Wien
Austria
Email: services@ares-genetics.com
http://www.globenewswire.com/news-release/2020/04/16/2017225/0/en/OpGen-Subsidiary-Ares-Genetics-Demonstrates-Feasibility-and-Potential-of-Next-Generation-Sequencing-Based-Antibiotic-Susceptibility-Testing-in-Multi-Center-Study.html
They need to release meaningful news for CV if they have anything legitimate about it; there is no better time to do so. Otherwise, we stuck in this stupid Channel.
I will get out in the next spike.
It is pretty hard to figure out what stocks you are in at any given moment
They were good yesterday (earning with enough cash and FDA pending approval off their kit).
Do you think that oil prices will go up by May? - it looks like the opening up of the country might be delayed.
I actually think that when we clear that level ($1.78), we shall run to the 50 MA at least in a heart beat ($2.5)
We need to clear $1.78 for a good run.
Oil stocks will need sometime to rebound as it seems.
When they announce the FDA approval, we will really fly like AIKI and WROX!!
Added $SM to my oil portfolio of $RIG and $CRC. Next 2-3 months should show a big rebound when the countries open up again.
They really killed the momentum for now-halt makes people nervous
May be AIKI is the next WORX...
Big boys want in IMO, no shares available. It is creating a mess in the system.
They killed all momentum..
A buy out of this company is written all over it IMO
$AIKI can run to $5, no shares available!!
It ran to $5.5 last time on much weaker news....
AIKI...$1.50...only 4 million outstanding shares...AIkido Pharma Executes Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus
NEW YORK, April 14, 2020 /PRNewswire/ -- AIkido Pharma Incorporated (Nasdaq: AIKI) today announced that it has secured an exclusive world-wide license for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens. The technology works to inhibit replication of multiple viruses including Influenza virus, SARS-COV (coronavirus), MERS-COV, Ebolavirus and Marburg virus.
https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1575107